Canaccord Genuity analyst Edward Nash maintained a Buy rating on Apogee Therapeutics yesterday and set a price target of $89.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Edward Nash has given his Buy rating due to a combination of factors, including Apogee Therapeutics’ strong financial position and promising pipeline developments. The company has a substantial cash reserve, bolstered by a recent equity offering, which positions it well for future growth and development.
Furthermore, Apogee is entering a critical phase with several key data readouts expected in 2026. These include the Phase Ib proof-of-concept readout for asthma and multiple phases of data for atopic dermatitis, which could significantly impact the company’s market position. The potential dosing advantage of APG777 over existing treatments like Dupixent further supports the positive outlook for Apogee’s therapeutic offerings.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $95.00 price target.
APGE’s price has also changed dramatically for the past six months – from $39.580 to $63.100, which is a 59.42% increase.